ID22763A - Komposisi penstabil tibolon - Google Patents

Komposisi penstabil tibolon

Info

Publication number
ID22763A
ID22763A IDW991204A ID991204A ID22763A ID 22763 A ID22763 A ID 22763A ID W991204 A IDW991204 A ID W991204A ID 991204 A ID991204 A ID 991204A ID 22763 A ID22763 A ID 22763A
Authority
ID
Indonesia
Prior art keywords
tibolon
stabilizer composition
dosage unit
tibolone
contained
Prior art date
Application number
IDW991204A
Other languages
English (en)
Indonesian (id)
Inventor
Pieter Haan De
Adrianus Cornelis Petru Rovers
Theodora Antonia Maria La Hurk
Jocorminus Antonius M Zwinkels
Ryoichi Morita
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ID22763A publication Critical patent/ID22763A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IDW991204A 1997-04-22 1998-04-20 Komposisi penstabil tibolon ID22763A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201180 1997-04-22

Publications (1)

Publication Number Publication Date
ID22763A true ID22763A (id) 1999-12-09

Family

ID=8228228

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991204A ID22763A (id) 1997-04-22 1998-04-20 Komposisi penstabil tibolon

Country Status (26)

Country Link
US (6) US6399594B2 (xx)
EP (1) EP0975348B1 (xx)
JP (1) JPH10316573A (xx)
KR (1) KR100580855B1 (xx)
CN (2) CN1146424C (xx)
AR (1) AR012480A1 (xx)
AT (1) ATE281836T1 (xx)
AU (1) AU742037B2 (xx)
BR (1) BR9809268A (xx)
CA (1) CA2288070A1 (xx)
DE (1) DE69827484T2 (xx)
DK (1) DK0975348T3 (xx)
ES (1) ES2232949T3 (xx)
HK (1) HK1023508A1 (xx)
HU (1) HUP0001780A3 (xx)
ID (1) ID22763A (xx)
IL (1) IL123984A (xx)
NO (1) NO995127L (xx)
NZ (1) NZ338028A (xx)
PL (1) PL190227B1 (xx)
PT (1) PT975348E (xx)
RU (1) RU2207133C2 (xx)
TR (1) TR199902530T2 (xx)
TW (1) TW570798B (xx)
WO (1) WO1998047517A1 (xx)
ZA (1) ZA983169B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100432093C (zh) 1998-10-16 2008-11-12 欧加农股份有限公司 包含（7α,17α)-17-羟基-7-甲基-19-去甲-17-孕-5（10）-烯-20-炔-3-酮的高纯度组合物
ES2316350T3 (es) * 1999-02-26 2009-04-16 SHIONOGI & CO., LTD. Capsulas blandas masticables con propiedades mejoradas de administracion y procedimiento para producirlas.
US20040229854A1 (en) * 2000-11-28 2004-11-18 Pieter Haan De Immediate release dosage form for HRT
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
JP5041651B2 (ja) * 2001-09-28 2012-10-03 ティーエヌティーギャンブル・インコーポレーテッド 生物体成分の送達系
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
CN1324041C (zh) * 2003-04-01 2007-07-04 上海迪赛诺医药科技开发有限公司 替勃龙晶型i的制备方法
DE602004016311D1 (de) * 2003-04-29 2008-10-16 Organon Nv Verfahren zur verfestigung, bei welchem ein anti-lösungsmittel benutzt wird
KR20050038590A (ko) * 2003-05-23 2005-04-27 엔.브이. 오가논 다형성 티볼론을 포함하는 즉시-방출형 약학 제형
EP1742615A2 (en) * 2004-05-05 2007-01-17 Akzo Nobel N.V. Antisolvent emulsion solidification process
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
WO2005120517A1 (en) * 2004-06-07 2005-12-22 Strides Arcolab Limited Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
CN102085193B (zh) * 2009-12-08 2013-11-06 北京以岭生物工程技术有限公司 一种替勃龙口腔崩解片及其制备方法
CN104345098B (zh) * 2013-08-05 2016-04-13 华润紫竹药业有限公司 一种测定替勃龙片剂中抗氧剂含量的方法
EP3452019B1 (en) 2016-05-04 2021-06-23 Novalon S.A. Use of sugar-alcohols in tibolone compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
CH676470A5 (xx) * 1988-02-03 1991-01-31 Nestle Sa
IE63051B1 (en) 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
DE69418744T2 (de) * 1993-03-05 1999-11-11 Akzo Nobel N.V., Arnheim/Arnhem Verwendung von Pregnanderivaten zur Behandlung von Tumoren
WO1995006461A1 (en) 1993-09-03 1995-03-09 Smithkline Beecham Corporation Stabilized tablet formulation
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water

Also Published As

Publication number Publication date
HUP0001780A2 (hu) 2000-12-28
ATE281836T1 (de) 2004-11-15
KR100580855B1 (ko) 2006-05-17
WO1998047517A1 (en) 1998-10-29
NO995127D0 (no) 1999-10-21
JPH10316573A (ja) 1998-12-02
PT975348E (pt) 2005-01-31
HUP0001780A3 (en) 2001-02-28
TR199902530T2 (xx) 2000-05-22
US6399594B2 (en) 2002-06-04
IL123984A (en) 2004-09-27
CA2288070A1 (en) 1998-10-29
CN1253503A (zh) 2000-05-17
PL190227B1 (pl) 2005-11-30
EP0975348A1 (en) 2000-02-02
AR012480A1 (es) 2000-10-18
US20040142031A1 (en) 2004-07-22
DE69827484D1 (de) 2004-12-16
NZ338028A (en) 2001-10-26
BR9809268A (pt) 2000-06-27
ZA983169B (en) 1998-10-20
US20040142030A1 (en) 2004-07-22
DE69827484T2 (de) 2005-03-17
HK1023508A1 (en) 2000-09-15
EP0975348B1 (en) 2004-11-10
US6514958B1 (en) 2003-02-04
US20030119801A1 (en) 2003-06-26
KR20010020163A (ko) 2001-03-15
PL336658A1 (en) 2000-07-03
US20010005513A1 (en) 2001-06-28
DK0975348T3 (da) 2005-03-07
TW570798B (en) 2004-01-11
CN1146424C (zh) 2004-04-21
CN1494908A (zh) 2004-05-12
AU8014698A (en) 1998-11-13
ES2232949T3 (es) 2005-06-01
RU2207133C2 (ru) 2003-06-27
NO995127L (no) 1999-10-21
AU742037B2 (en) 2001-12-13
US20040142028A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
ID22763A (id) Komposisi penstabil tibolon
SE9700135D0 (sv) New formulation
MY118371A (en) Tetrahydrolipstatin containing compositions
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
ES8402155A1 (es) Un metodo para producir formas posologicas unitarias solidas que al administrarse siguen una pauta de liberacion regular y prolongada.
EP0693924A4 (en) METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS
ATE329608T1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
BR9810495A (pt) Composição farmacêutica
IE891414L (en) Pharmaceutical compositions
IL101056A (en) Composition for nasal treatment
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
FI870457A0 (fi) Farmaceutiska preparatformer foer stabilisering av interferon- .
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
BG94934A (bg) Твърди лекарствени форми за орално приложение,съдържащи ифосфамид като активно вещество
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
GB2258397A (en) Pharmaceutical compositions containing amethocaine
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
NZ241309A (en) Heterocyclic amido prostaglandin analogues, preparation and pharmaceutical compositions thereof
KR970058720A (ko) 향균 및 항진균 활성을 갖는 펩타이드
ITRM910038A1 (it) Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.
ATE130190T1 (de) Ein dihydropyridinderivat in nanosolform enthaltendes retard-arzneimittel und seine herstellung.
GB8902069D0 (en) Pharmaceutical composition comprising 3-(n-piperidino-azino)methylrifamycin s as active ingredient
GB9005316D0 (en) Pharmaceutical composition comprising 3-(n-piperidinomethyl-azino)methylrifamycin s as active ingredient